New hope for blood cancer patients after other treatments fail

This study aims to see how well the drug Tazemetostat works for adults with follicular lymphoma, a slow-growing blood cancer, that has come back or stopped responding to at least two prior treatments. Doctors will observe patients receiving Tazemetostat in real-world settings to measure how many people respond to the drug, how long the response lasts, and what side effects occur. The results will also be analyzed based on whether patients have a specific genetic mutation.